MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

XBiotech Inc

Uždarymo kaina

3.01 -5.64

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.01

Max

3.15

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-5.5M

-11M

Pelnas, tenkantis vienai akcijai

-0.165

Darbuotojai

92

EBITDA

-5.5M

-9.9M

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-08

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.8M

105M

Ankstesnė atidarymo kaina

8.65

Ankstesnė uždarymo kaina

3.01

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

XBiotech Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-31 22:45; UTC

Svarbiausios naujienos

Intel's New CEO Plots Turnaround; 'We Need to Improve'

2025-03-31 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise After Monday's Selloff -- Market Talk

2025-03-31 23:44; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

2025-03-31 23:15; UTC

Rinkos pokalbiai

Tower Shares Ease After Bain Capital Exit -- Market Talk

2025-03-31 23:15; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-03-31 22:33; UTC

Svarbiausios naujienos

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

2025-03-31 22:28; UTC

Uždarbis

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

2025-03-31 22:28; UTC

Uždarbis

China Vanke Swings to Loss for 2024 >000002.SZ

2025-03-31 21:47; UTC

Svarbiausios naujienos

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

2025-03-31 21:44; UTC

Svarbiausios naujienos

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

2025-03-31 21:21; UTC

Rinkos pokalbiai

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

2025-03-31 21:18; UTC

Svarbiausios naujienos

Copper Is 2025's Hottest Commodity -- Update

2025-03-31 21:09; UTC

Svarbiausios naujienos

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

2025-03-31 21:02; UTC

Uždarbis

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

2025-03-31 21:01; UTC

Uždarbis

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

2025-03-31 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-03-31 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-03-31 20:37; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

2025-03-31 20:17; UTC

Svarbiausios naujienos

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

2025-03-31 20:13; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

2025-03-31 20:03; UTC

Svarbiausios naujienos

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

2025-03-31 19:09; UTC

Rinkos pokalbiai

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

2025-03-31 18:56; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains With Help From Weather -- Market Talk

2025-03-31 18:54; UTC

Rinkos pokalbiai

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

2025-03-31 18:40; UTC

Rinkos pokalbiai

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

2025-03-31 18:34; UTC

Rinkos pokalbiai

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

2025-03-31 18:28; UTC

Rinkos pokalbiai

Gold Climbs to Close Out Quarter -- Market Talk

2025-03-31 18:03; UTC

Svarbiausios naujienos

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Akcijų palyginimas

Kainos pokytis

XBiotech Inc Prognozė

Techninis įvertinimas

By Trading Central

3.1 / 3.4405Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę XBiotech Inc

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.